595
Participants
Start Date
February 28, 2005
Primary Completion Date
May 31, 2008
Study Completion Date
September 30, 2014
Cyclosporin A
tablet, oral, 1st month target: 150-300 ng/mL, after 1st month target: 100-250 ng/mL, daily, 36 months, 100-250 ng/mL, daily, 84 months
Belatacept Less Intensive Regimen (LI)
solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months months, 5 mg/kg every 4 weeks, q 4 weeks, 84 months
Belatacept More Intensive Regimen (MI)
solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months, 5 mg/kg every 4 weeks, q 4 weeks, 84 months
Local Institution, Budapest
Local Institution, Vienna
Local Institution, Capital Federal
Local Institution, Rosario
Local Institution, Leuven
Local Institution, Woodville
Local Institution, Innsbuck
Mount Sinai School Of Medicine, New York
Columbia University College Of Physicians & Surgeons, New York
Local Institution, Berlin
Local Institution, Campinas/sp
Local Institution, Berlin
Drexel University College Of Medicine, Department Of Surgery, Philadelphia
University Of Pennsylvania, Philadelphia
Local Institution, Milan
Local Institution, Rio de Janeiro
University Of North Carolina At Chapel Hill, Chapel Hill
Local Institution, Madrid
Local Institution, Madrid
Carolinas Medical Center, Charlotte
Local Institution, Málaga
Local Institution, Brest
Piedmont Transplant Institute, Atlanta
Emory University Hospital, Atlanta
Local Institution, Hanover
Local Institution, Toulouse
Local Institution, Bordeaux
Lifelink Healthcare Institute, Tampa
Local Institution, Padua
University Of Alabama At Birmingham, Birmingham
Local Institution, Tours
Local Institution, Nantes
Local Institution, Essen
Henry Ford Hospital, Transplant Institute, Detroit
Froedtert Memorial Hospital, Milwaukee
University Of Wisconsin, Madison
Local Institution, Vandœuvre-lès-Nancy
University Of Minnesota, Minneapolis
Northwestern University-Feinberg School Of Medicine, Chicago
University Of Chicago Hospitals, Chicago
Washington University School Of Medicine, St Louis
Tulane Abdominal Transplant Institute, New Orleans
Acadiana Renal Physicians, New Iberia
Local Institution, Paris
Baylor University Medical Center, Dallas
University Of Colorado Health Sciences Center, Aurora
Ucla Kidney & Kidney-Pancreas Transplant Research Office, Los Angeles
Local Institution, Porto Alegre
Local Institution, Porto Alegre/rs
National Institute Of Transplantation, Los Angeles
Local Institution, Erlangen
Sharp Memorial Hospital, San Diego
Local Institution, Créteil
University Of California San Francisco Medical Center, San Francisco
Local Institution, Le Kremlin-Bicêtre
Yale University School Of Medicine, New Haven
Beth Israel Deaconess Medical Center, Boston
Western New England Renal & Transplant Associates, Pc, Springfield
Local Institution, Capital Federal
Local Institution, Cordoba, Crd
Local Institution, Santa Fe
Local Institution, São Paulo
Local Institution, São Paulo
Local Institution, Edmonton
Local Institution, Halifax
Local Institution, Montreal
Local Institution, Saskatoon
Local Institution, Santiago
Local Institution, Prague
Local Institution, Szeged
Local Institution, Roma
Local Institution, Oslo
Local Institution, Poznan
Local Institution, Warsaw
Local Institution, Pretoria
Local Institution, Barcelona
Local Institution, Barcelona
Local Institution, Gothenburg
Local Institution, Manchester
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY